Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.
Department of Medical Physics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Radiat Prot Dosimetry. 2020 Jul 13;189(2):213-223. doi: 10.1093/rpd/ncaa033.
The aim of this study is the calculation of equivalent organ dose and estimation of lifetime attributable risk (LAR) of cancer incidence and mortality related to cardiac computed tomography angiography (CCTA) because the use of CT angiography as a noninvasive diagnostic method has increased. The organ dose has been calculated by ImPACT software based on the volumetric CT dose index (CTDIvol), and LAR of cancer risk incidence and mortality from CCTA has estimated according to the BEIR VII report. The median value of the effective dose was 13.78 ± 6.88 mSv for both genders. In all scanners, the highest median value for LAR of cancer incidence in males and females for lung cancer was 44.20 and 109.17 per 100 000, respectively. And in infants was 5.89 and 12 for lung cancer in males and breast cancer in females, respectively. Also, the median value of LAR of all cancer incidence from single CCTA in adult patients for males and females was 122 and 238 cases, respectively. Maximum LAR of cancer mortality in adults for lung cancer was 40.28 and 91.84 and in pediatrics was 5.69 and 8.50 in males and females, respectively. Despite many benefits of CTA in the heart disease evaluation, according to a high radiation dose in CCTA, to reduce the cancer risk: CCTA should be used cautiously, especially for pediatric and females.
本研究旨在计算与心脏 CT 血管造影（CCTA）相关的器官当量剂量和估计癌症发病和死亡的终身归因风险（LAR），因为 CT 血管造影作为一种非侵入性诊断方法的使用有所增加。器官剂量是通过基于容积 CT 剂量指数（CTDIvol）的 ImPACT 软件计算的，根据 BEIR VII 报告估算了 CCTA 相关癌症风险发病率和死亡率的 LAR。对于男性和女性，有效剂量的中位数分别为 13.78 ± 6.88 mSv。在所有扫描仪中，男性和女性肺癌的 LAR 发病率的中位数最高值分别为 44.20 和 109.17 每 100000 例。对于男性的肺癌和女性的乳腺癌，婴儿的中位数分别为 5.89 和 12。此外，对于男性和女性的成年患者单次 CCTA 的所有癌症发病率的 LAR 中位数分别为 122 和 238 例。成年人肺癌的最大癌症死亡率 LAR 分别为 40.28 和 91.84，儿科为 5.69 和 8.50，男性和女性分别为 5.69 和 8.50。尽管 CTA 在心脏病评估中有许多好处，但根据 CCTA 的高辐射剂量，为了降低癌症风险：应谨慎使用 CCTA，尤其是儿科和女性。
